MedTrace Logo

To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

NCT05818982 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-04-19

No results posted yet for this study

Summary

This is a phase II study to evaluate the effectiveness and safety of Afininib compared to irinotecan in the 3-gene RNA sequencing (ALTRK) negative advanced esophageal squamous squamous carcinoma.

Conditions

  • Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Afatinib

Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.

DRUG

Irinotecan

Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D

Sponsors & Collaborators

  • Peking University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-09
Primary Completion
2025-02-28
Completion
2026-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05818982 on ClinicalTrials.gov